Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OIG Report on Supplement Claims Finds Disease Claims, Substantiation Issues

This article was originally published in The Tan Sheet

Executive Summary

The HHS Office of the Inspector General finds a number of issues with supplement structure/function claims, and makes several recommendations to FDA to reduce illegal claims and weak substantiation.

You may also be interested in...



Ingredient Safety Concerns Rise Among FDA Enforcement Priorities

Ingredient safety, new dietary ingredient notifications, adverse event reporting, claims substantiation and disease claims are all drawing FDA attention in the supplement space, Daniel Fabricant says. Compliance for good manufacturing practices still heads the priorities for enforcement, he says.

Ingredient Safety Concerns Rise Among FDA Enforcement Priorities

Ingredient safety, new dietary ingredient notifications, adverse event reporting, claims substantiation and disease claims are all drawing FDA attention in the supplement space, Daniel Fabricant says. Compliance for good manufacturing practices still heads the priorities for enforcement, he says.

Tainted Supplement Recalls Prompt Call For Tighter Regulations – Letter

A research letter says that tainted supplements accounted for more than half of class I recalls from 2004-2012, and the researchers argue for stricter regulation. Industry points to a steep drop-off after 2010, and call for stronger enforcement of existing regulations.

Related Content

Topics

UsernamePublicRestriction

Register

PS106006

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel